We are a clinical-stage biopharmaceutical company focused on the development of chimeric antigen receptor (CAR) T-lymphocytes (T-cells), or CAR-T, cell-based therapies for the treatment of cancer.
Last Closing Price
September 12, 2019
WELLS FARGO SECURITIES, LLC
This offering is no longer available
Sign Up to participate in future offerings
To view the prospectus for CELYAD S.A., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277